We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+4.02%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$14.7B
AUM Growth
-$14.5M
Cap. Flow
+$16.2M
Cap. Flow %
0.11%
Top 10 Hldgs %
85.95%
Holding
111
New
8
Increased
15
Reduced
6
Closed
2

Top Buys

Rank Stock Value
1
NVTA
Invitae Corporation
NVTA
+$115M
2
IGMS
IGM Biosciences
IGMS
+$63.5M
3
ACAD icon
Acadia Pharmaceuticals
ACAD
+$47.4M
4
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$26.6M
5
URGN icon
UroGen Pharma
URGN
+$24.4M

Top Sells

Rank Stock Value
1
ARRY
Array Biopharma Inc
ARRY
+$132M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$113M
3
CPRX
Catalyst Pharmaceutical
CPRX
+$6.49M
4
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$5.15M
5
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$4.91M

Sector Composition

Rank Sector Weight
1 Healthcare 93.54%
2 Financials 0.01%
3 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABEO icon
76
Abeona Therapeutics
ABEO
$355M
$2.91M 0.02%
51,529
– –
GTHX
77
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$2.9M 0.02%
127,236
– –
DOVA
78
DELISTED
Dova Pharmaceuticals, Inc. Common Stock
DOVA
$2.86M 0.02%
102,205
+2,800
+3% +$45.4K
BLCM
79
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$2.81M 0.02%
267,782
– –
YMAB
80
DELISTED
Y-mAbs Therapeutics
YMAB
$2.68M 0.02%
102,800
– –
CRNX icon
81
Crinetics Pharmaceuticals
CRNX
$8.88B
$2.63M 0.02%
175,000
+42,015
+32% +$817K
CYCN icon
82
Cyclerion Therapeutics
CYCN
$15.2M
$2.46M 0.02%
10,129
– –
FSTX
83
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$2.11M 0.01%
153,286
– –
AUTL
84
Autolus Therapeutics
AUTL
$386M
$1.95M 0.01%
156,773
– –
IDYA icon
85
IDEAYA Biosciences
IDYA
$3.48B
$1.8M 0.01%
200,000
– –
NTLA icon
86
Intellia Therapeutics
NTLA
$1.55B
$1.72M 0.01%
128,538
– –
MTEM
87
DELISTED
Molecular Templates, Inc.
MTEM
$1.68M 0.01%
16,949
– –
FTSV
88
DELISTED
Forty Seven, Inc. Common Stock
FTSV
$1.6M 0.01%
250,000
– –
FOMX
89
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$1.51M 0.01%
498,189
– –
CTMX icon
90
CytomX Therapeutics
CTMX
$708M
$1.44M 0.01%
194,377
– –
CCXI
91
DELISTED
ChemoCentryx, Inc.
CCXI
$1.4M 0.01%
207,029
– –
FLGT icon
92
Fulgent Genetics
FLGT
$566M
$1.3M 0.01%
125,000
– –
MTNB icon
93
Matinas BioPharma
MTNB
$1.8M
$1.25M 0.01%
+39,699
New +$1.43M
CYPH
94
Cypherpunk Technologies Inc
CYPH
$65.4M
$1.15M 0.01%
+97,845
New +$1.69M
RCUS icon
95
Arcus Biosciences
RCUS
$3.37B
$1.11M 0.01%
121,534
– –
GLMD icon
96
Galmed Pharmaceuticals
GLMD
$4.46M
$1.03M 0.01%
1,198
– –
ADMS
97
DELISTED
Adamas Pharmaceuticals
ADMS
$883K 0.01%
172,630
– –
CNST
98
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$861K 0.01%
133,333
– –
SRRA
99
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$781K 0.01%
50,000
– –
INFI
100
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$598K ﹤0.01%
580,400
– –
1 2 3
4
5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q3 2019 Portfolio in Review

As of Q3 2019, Baker Bros. Advisors held 111 positions worth $14.7B, down 0.1% from $14.7B the previous quarter. Its ten largest holdings account for 86% of the portfolio.

Baker Bros. Advisors's Q3 2019 filing shows 8 new, 15 increased, 6 reduced and 2 closed positions. Its largest new stake was IGM Biosciences: 3,144,000 shares worth $55.8M. The largest sale was Array Biopharma Inc, an estimated $132M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 95% a quarter earlier, followed by Financials and Technology.

  • Baker Bros. Advisors's largest Q3 2019 buy was IGM Biosciences: 3,144,000 shares worth $55.8M.
  • Baker Bros. Advisors added most to Invitae Corporation in Q3 2019, an estimated $115M increase.
  • Baker Bros. Advisors's biggest Q3 2019 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $113M.
  • Baker Bros. Advisors fully exited Array Biopharma Inc in Q3 2019, selling an estimated $132M.
  • Baker Bros. Advisors's ten largest holdings make up 86% of its $14.7B portfolio in Q3 2019.
  • Baker Bros. Advisors opened 8 new positions and closed 2 in Q3 2019.
  • Baker Bros. Advisors's portfolio value fell 0.1% quarter-over-quarter to $14.7B.

Based on Baker Bros. Advisors's 13F filing for Q3 2019, filed 14 Nov 2019.